Collecting CAR parts

How Cell Medica plans to use Delenex, Baylor tech in CAR platform for solid tumors

While CAR T cell therapies have produced impressive response rates in blood cancers, the approach has so far shown limited effect in solid tumors, partly due to poor localization of T cells in tumor sites. Cell Medica Ltd. has therefore been assembling a tool kit to develop and improve upon a chimeric antigen receptor natural killer T cell platform.

Unlike T cells, which circulate in the blood, NKT cells localize in solid tumors in response to chemokines produced by tumor cells.

The first step was a June deal with Baylor College of Medicine to co-develop CAR NKT cell therapies to treat cancer.

The second step was

Read the full 1062 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE